Navigation Links
Radient Pharmaceuticals Announces Proxy Resolutions Approved at Special Meeting of Stockholders
Date:11/4/2011

TUSTIN, Calif., Nov. 4, 2011 /PRNewswire/ -- Radient Pharmaceuticals Corporation (OTCQX:RXPC) (OTCPK:RXPC), a developer and marketer of In Vitro Diagnostic (IVD) cancer tests, today announced that all six proxy resolutions passed at a special meeting of shareholders today.

The Company's proxy statement was filed with the Securities and Exchange Commission on October 14, 2011 is available at www.sec.gov and on the Company's web site:  www.radient-pharma.com Radient Pharmaceuticals also announced that it has retained E & E Communications, Laguna Hills, California, and its principal, Paul Knopick, to assist with its public and investor relations program.

The following table is intended to provide the latest information on Radient's business metrics.Radient's Business MetricsCash on hand: $165,000*

*Approximate amount as of November 2, 2011Common Shares Outstanding:  647 million*

*Approximate number as of November 2, 2011.

  750 million shares authorized.Outstanding Warrants & Options:  110 million*

*Approximate number as of November 2, 2011About Radient Pharmaceuticals:Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® cancer test kit for colorectal cancer treatment and recurrence monitoring. The Company's focus is on the discovery, development and commercialization of unique high-value diagnostic tests that will help physicians answer important clinical questions related to early disease state detection, treatment strategy, and the monitoring of disease progression or recurrence. To learn more about our company, products, and potentially life-saving cancer test, visit www.radient-pharma.com
'/>"/>

SOURCE Radient Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. BellBrook Labs Launches Groundbreaking New Microplate for High Content Chemotaxis Assays in a Stable Gradient
2. Thermal Gradient Announces Breakthrough in Fast PCR Device Technology
3. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
4. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
5. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
6. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
7. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
8. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
9. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
10. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
11. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Mich. Every day, their baby stopped breathing, his ... his lungs. April and Bryan Gionfriddo watched helplessly, just ... "Quite a few doctors said he had a good ... Gionfriddo, about her now 20-month-old son, Kaiba. "At that ... would take it and run with it." , They ...
(Date:5/23/2013)... ROCK, Colo. , May 23, 2013 ... diagnostic company focused on obtaining FDA clearance and ... , today announced the pricing of an underwritten public ... related warrants to purchase 3,500,000 shares of its common ... at a combined public offering price of $1.25 per ...
(Date:5/23/2013)... N.Y. , May 23, 2013  BioScrip, Inc. ... Company will present at the Jefferies 2013 Global Healthcare ... Grand Hyatt New York. Richard ... Hai Tran , Chief Financial Officer, ... a.m. Eastern Daylight Time.   About BioScrip ...
(Date:5/23/2013)... May 23, 2013 Can economic incentives ... work motivate members of the public to increase their ... Johns Hopkins Carey Business School Assistant Professor ... Pointing to a large body of recent research that ... May 24, 2013, issue of Science that the World ...
Breaking Biology Technology:Baby's life saved with groundbreaking 3-D printed device that restored his breathing 2Baby's life saved with groundbreaking 3-D printed device that restored his breathing 3Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 2Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 3
... 10, 2011 GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), an ... and fight Human Immunodeficiency Virus (HIV) infections, today announced ... 30, 2011. GeoVax reported a net loss ... ended September 30, 2011, compared to $644,666 ($0.04 per ...
... Theravalues, a Japan based bio-venture, announced today ... prevention of heart failure and its progression for the ... started with the registration in July 2010, conducted by ... and University of Shizuoka, Japan, the researchers found that ...
... Research has expanded its research footprint to support ... offering high-quality biospecimens coupled with unprecedented premium data ... with AdeptBio, LLC ( http://www.adeptbio.com ).   ... services as needed to facilitate prospective collections of ...
Cached Biology Technology:GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results 2GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results 3GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results 4GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results 5Theravalues Confirms Beneficial Effects of Theracurmin™ on Diastolic Function in Hypertensive Patients 2ACORN Research, LLC Announces Partnership with AdeptBio, LLC 2
(Date:5/23/2013)... , Automated conserved noncoding sequence (CNS) ... among grasses , Within the genome of each ... undergo little change in position and sequence over millions ... Some of these evolutionarily stable sequences, so-called conserved noncoding ... other genes or the condensation of chromosomes, but the ...
(Date:5/23/2013)... said to be the world,s most popular fruit, can ... research with purple GM varieties. , "Working with ... by the addition of a specific compound, allows us ... said Professor Cathie Martin from the John Innes Centre. ... with better flavour, health and shelf life characteristics because ...
(Date:5/23/2013)... RICHLAND, Wash. Pacific Northwest National Laboratory honored ... and commercialization of intellectual property at PNNL,s annual ... , The Department of Energy national laboratory ... Year for his work developing battery materials that ... to the electrical grid, and reduce the time ...
Breaking Biology News(10 mins):Frontiers news briefs: May 23 2Frontiers news briefs: May 23 3The world's favorite fruit only better-tasting and longer-lasting 2PNNL staff recognized for scientific accomplishments, moving technologies into the marketplace 2
... DC Cancer researchers at Georgetown University,s Lombardi Comprehensive ... they say shuts down growth of human glioblastoma tumors ... of brain cancers; there is no effective treatment. In ... researchers demonstrate how this antibody latches onto a receptor ...
... joined forces in a groundbreaking assessment of the status of ... fishery ecosystem scientist from the CSIRO Wealth from Oceans Flagship, ... report on a two-year study, led by US scientists Dr ... the University of Washington. The study shows that steps ...
... A new approach to windows that could let in ... to 99% in buildings in Tropical regions without losing ... the International Journal of Engineering Systems Modelling and ... in the School of Environment, Resources and Development, at ...
Cached Biology News:Antibody targeting of glioblastoma shows promise in preclinical tests, say Lombardi researchers 2Antibody targeting of glioblastoma shows promise in preclinical tests, say Lombardi researchers 3Global curbs on overfishing are beginning to work 2Opening a new window on daylight 2
with GlutaMAXIL-glutamine...
Request Info...
... peptide derived from the C terminal region ... This peptide sequence is downstream from the ... Connexin 36 antibody Cat. No. 51-6300. ... Reactivity: Mouse (positive control: mouse Connexin 36-transfected ...
Request Info...
Biology Products: